Pantoprazol Hikma (Pantoprazole)

Pantoprazol Hikma is a proton pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related conditions:

• Gastro‑oesophageal reflux disease (GERD): provides symptomatic relief and promotes healing of the oesophageal lining.
• Erosive oesophagitis: heals erosive lesions and prevents further damage.
• Peptic ulcer disease: supports ulcer healing and reduces recurrence risk.
• Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with the condition.

• Pantoprazole selectively inhibits the H+/K+‑ATPase enzyme (the gastric proton pump) located on the secretory surface of parietal cells. By binding irreversibly to this pump, it blocks the final step of acid production, leading to a sustained decrease in gastric acidity and allowing mucosal healing.

Pantoprazol Hikma may cause adverse reactions, most of which are mild and reversible.

Common Side Effects

• Headache: mild to moderate intensity.
• Diarrhoea: watery stools without blood.
• Nausea: occasional feeling of queasiness.
• Abdominal pain: mild cramping.
• Flatulence: increased intestinal gas.
• Constipation: infrequent, hard stools.

Serious or Rare Side Effects

• Severe allergic reaction: rash, itching, swelling, or difficulty breathing.
• Clostridioides difficile infection: persistent diarrhoea with abdominal pain.
• Low magnesium levels: muscle cramps, irregular heartbeat, or seizures.
• Liver enzyme elevation: asymptomatic rise in hepatic transaminases.
• Fracture risk: increased incidence of hip, wrist or spine fractures with long‑term use.

When prescribing Pantoprazol Hikma, consider the following safety measures:

• Assess renal function: adjust use in severe renal impairment.
• Evaluate bone health: monitor patients at risk for fractures during prolonged therapy.
• Review concomitant medications: potential for altered absorption of drugs requiring acidic pH.
• Pregnancy and lactation: use only if clearly needed after risk‑benefit assessment.
• Elderly patients: start with the lowest effective dose and monitor for adverse effects.
• Store at ambient temperature: keep below 25°C, protect from moisture and light.

Pantoprazol Hikma can affect the pharmacokinetics of several medicines. Awareness of these interactions helps maintain therapeutic effectiveness.

Major Interactions (Avoid)

• Ketoconazole or itraconazole: reduced antifungal absorption leading to treatment failure.
• Atazanavir: markedly decreased antiviral levels, compromising HIV therapy.

Moderate Interactions (Monitor Closely)

• Warfarin: possible increase in INR, requiring more frequent coagulation monitoring.
• Digoxin: slight rise in serum concentrations, may need dose adjustment.
• Methotrexate: reduced clearance can increase toxicity, especially at high doses.
• Iron supplements: decreased iron absorption, consider timing separation.